Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on two deals, the first to divest a portfolio of pharmaceutical products currently licensed and marketed by Hikma Pharmaceuticals PLC (Hikma) for select territories in the Middle East and North Africa (MENA) region, the second to divest the oncological product MEPACT (mifamurtide) to Esteve Pharmaceutical S.A. (Esteve).
Both divestments are subject to customary legal and regulatory closing conditions including, among other things, antitrust clearances and are expected to close during 2025.
White & Case has advised Takeda on a number of divestitures since 2019, covering select over-the-counter and prescription pharmaceutical products in Europe, the Near East, Middle East and Africa, Georgia, a number of countries in the Commonwealth of Independent States, Latin America and Asia-Pacific.
Takeda is a leading global biopharmaceutical company headquartered in Japan that is primarily focused on gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. Hikma is a UK-listed global pharmaceutical company with a presence across North America, MENA and Europe. Esteve is a Spain-headquartered global pharmaceutical company with a presence in Europe.
The White & Case team that advised on the above transactions was led by partners Michael Immordino (London & Milan) and Leonardo Graffi (Milan & London) and included partners Philip Trillmich (London & Frankfurt) and Strati Sakellariou-Witt (Brussels), local partner Andrea Pretti (Milan) and associates Tommaso Poli and Giulio Preti (both Brussels & Milan).
Press contact
For more information please speak to your local media contact.
